1992
DOI: 10.1128/aac.36.1.202
|View full text |Cite
|
Sign up to set email alerts
|

The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro

Abstract: Racemic 2'-deoxy-3'-thiacytidine (BCH 189) is a dideoxycytidine analog having a sulfur atom in place of the 3' carbon. The enantiomers of BCH 189 have been resolved and found to be equipotent in antiviral activity against human immunodeficiency virus types 1 and 2. However, the (-)-enantiomer (3TC) is considerably less cytotoxic than the (+)-enantiomer.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

1
138
0

Year Published

1993
1993
2018
2018

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 291 publications
(139 citation statements)
references
References 15 publications
1
138
0
Order By: Relevance
“…Two analogues of cytosine, cis-1-[2-(hydroxymethyl)-1 ,3-oxathiolane-5-yl]cytosine (BCH 189; Fig. 1b) and cis-e-fluoro-t-[2-(hydroxymethyl)-1,3-oxathiolane-5-yl]cytosine (FTC; Fig.1c), have extremely potent activity against both HIV-1 and HBV (Doong et el., 1991;Coats et al, 1992a;Coats et et., 1992b;Furman et al, 1992;Schinazi et al, 1992) (Table 1). However, BCH…”
Section: Dideoxycytidine Analogues: 3tc Ftc Ddc and Fddcmentioning
confidence: 99%
“…Two analogues of cytosine, cis-1-[2-(hydroxymethyl)-1 ,3-oxathiolane-5-yl]cytosine (BCH 189; Fig. 1b) and cis-e-fluoro-t-[2-(hydroxymethyl)-1,3-oxathiolane-5-yl]cytosine (FTC; Fig.1c), have extremely potent activity against both HIV-1 and HBV (Doong et el., 1991;Coats et al, 1992a;Coats et et., 1992b;Furman et al, 1992;Schinazi et al, 1992) (Table 1). However, BCH…”
Section: Dideoxycytidine Analogues: 3tc Ftc Ddc and Fddcmentioning
confidence: 99%
“…5,6 Furthermore, the engineering, prediction and understanding of salt formation are based on elegant chemical approaches on assembly mechanisms driven by molecular recognition events, which contribute to an easier legal process for protection of intellectual property on novel API crystal phases due to nonobviousness of designed molecular salts. Lamivudine (b-L-2 0 ,3 0 -dideoxy-3 0 -thiacytidine, 3TC) belongs to the class of nucleoside reverse transcriptase inhibitors (NRTIs), and it is being used worldwide in anti-HIV therapy 8 and also against hepatitis B virus.…”
mentioning
confidence: 99%
“…39) Indeed, the L-isomer of lamivudine was more potent and less cytotoxic than its D-isomer. [40][41][42][43] We concluded that our synthetic approach was effective. Adopting a similar synthetic scheme for the D-isomers depicted above, we were able to obtain L-4′-thioarabinonucleosides from D-xylose by shifting the chiral carbons employed.…”
Section: Synthesis Of L-isomers Of 4′-thionucleosidesmentioning
confidence: 89%